Pfizer shares set a 52-week high at $29.09 after Q2 2026 earnings beat and Depo-Provera settlement
AI Market Summary
Pfizer shares hit a 52-week high after Q2 FY2026 results beat expectations on EPS and revenue and management raised full-year revenue guidance. A confidential settlement covering 6,000+ Depo-Provera federal lawsuits removes a major legal overhang, reducing uncertainty around future cash flows. Higher-than-normal trading volume suggests renewed investor attention, though consensus ratings remain mixed.
Impact level
● Medium
Affected assets
NCSKPFE2USD/USDT+0.71%
AI Insight · NCSKPFE2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Pfizer shares touched a 52-week high of $29.09 on Tuesday and last traded at $28.75. The company reported Q2 2026 adjusted EPS of $0.77 on revenue of $15.03B, beating expectations of $0.68 and $14.42B. Pfizer also raised its full-year 2026 revenue outlook and said it reached a settlement covering more than 6,000 federal Depo-Provera lawsuits, removing a major legal overhang.
